Table 2.
The 5-year age- and sex-adjusted prevalence rates
| Outcome | All individuals | Obese class 1 | Obese class 2 | Obese class 3 |
|---|---|---|---|---|
| 5-Year prevalence rate (95% CI) | ||||
| Individual components of the cardiovascular outcome | ||||
| Acute care visit with accompanying diagnosis of heart failure | 8.4 (7.9–8.8) | 6.1a,c (5.6–6.7) | 7.7a,b (6.9–8.5) | 12.4b,c (11.4–13.5) |
| Myocardial infarction | 4.4 (4.0–4.7) | 3.9 (3.5–4.4) | 4.7 (4.1–5.3) | 4.4 (3.7–5.0) |
| Stroke | 7.5 (7.1–7.9) | 7.0 (6.4–7.6) | 6.7 (6.0–7.4) | 7.6 (6.7–8.4) |
| Individual components of the microvascular outcome | ||||
| Neuropathy | 39.5 (38.8–40.3) | 34.7c (33.7–35.8) | 36.3b (34.9–37.7) | 45.2b,c (43.6–46.8) |
| Nephropathy | 30.0 (29.3–30.7) | 29.2c (28.2–30.2) | 29.7 (28.4–31.1) | 32.3c (30.8–33.8) |
| Retinopathy | 23.5 (22.9–24.2) | 23.5 (22.5–24.4) | 23.5 (22.3–24.7) | 24.0 (22.7–25.4) |
| Secondary outcomes | ||||
| ASCVD | 81.9 (81.3–82.5) | 77.1a,c (76.1–78.0) | 81.5a,b (80.4–82.6) | 85.5b,c (84.3–86.6) |
| Atrial fibrillation | 9.2 (8.8–9.7) | 7.7c (7.1–8.3) | 8.7b (7.9–9.5) | 12.7b,c (11.7–13.8) |
| Liver cirrhosis | 24.3 (23.6–24.9) | 20.2c (19.3–21.1) | 21.9b (20.7–23.1) | 28.7b,c (27.3–30.2) |
| NASH/NAFLD | 20.9 (20.2–21.5) | 17.0a,c (16.2–17.9) | 20.5a,b (19.3–21.6) | 23.2b,c (21.8–24.5) |
| Obstructive sleep apnea | 32.1 (31.4–32.9) | 19.4a,c (18.5–20.3) | 31.2a,b (29.9–32.5) | 47.2b,c (45.7–48.8) |
ASCVD Atherosclerotic cardiovascular disease, CI confidence interval, eGFR estimated glomerular filtration rate, NAFLD non-alcoholic fatty liver disease, NASH non-alcoholic steatohepatitis
aStatistically significant difference between obese class 1 and obese class 2 (P < 0.05)
bStatistically significant difference between obese class 2 and obese class 3 (P < 0.05)
cStatistically significant difference between obese class 1 and obese class 3 (P < 0.05)